Momenta Pharmaceuticals Stock News

Technically speaking, the U.S. benchmarks have registered a mid-July market whipsaw, writes Michael Ashbaugh, pressured at least briefly amid the month’s...

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market

Annexon aims to raise $100 million in an IPO, although the final figure may differ. The firm is advancing treatments for various autoimmune and neurodegenerative disorders.

Technically speaking, the major U.S. benchmarks are off to a constructive July start despite persistently uneven price action, writes Michael Ashbaugh.

Top Ranked Momentum Stocks to Buy for July 6th

Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations

FDx Advisors Inc. acquired a new position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) during the 1st quarter, according to the company in its most recent disclosure with the Securities an

Technically speaking, the major U.S. benchmarks are poised to conclude June against an increasingly uneven, but still generally bullish, bigger-picture...

The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has been given an average recommendation of “Buy” by the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two anal

Momenta (MNTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

Momenta Pharmaceuticals (NASDAQ:MNTA)‘s stock had its “buy” rating reaffirmed by Stifel Nicolaus in a report issued on Wednesday, TipRanks reports. Several other analysts also recently commented

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Momenta Pharma (MNTA – Research Report) today. The company’s shares

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc...